KRAS and non-small cell lung carcinoma: In the case of radiotherapy, the major treatment of NSCLC, hypoxia due to disorganized vasculature, cancer stem cells and mutational status (e.g., EGRF, KRAS, etc.)are believed to be among the key factors in resistance [90].